Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.

@article{Inaba2012EffectsOL,
  title={Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.},
  author={Wataru Inaba and Hiroki Mizukami and Kosuke Kamata and Kazunori Takahashi and Kentaro Tsuboi and Soroku Yagihashi},
  journal={European journal of pharmacology},
  year={2012},
  volume={691 1-3},
  pages={297-306}
}
Reduced β cell mass is a characteristic feature of type 2 diabetes and incretin therapy is expected to prevent this condition. However, it is unknown whether dipeptidyl peptidase-4 inhibitors influence β and α cell mass in animal models of diabetes that can be translated to humans. Therefore, we examined the long-term effects of treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet morphology in Goto-Kakizaki (GK) rats, a spontaneous, non-obese model of type 2 diabetes, and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat

J. A. Ehsesa, G. Lacrazb, +8 authors M. Y. Donatha
2009
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…